OncoMatch/Clinical Trials/NCT06014190
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Is NCT06014190 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies HS-20089 for ovarian cancer.
Treatment: HS-20089 — HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a protease-cleavable linker, with an average drug-to-antibody ratio of about 6. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20089 as monotherapy in patients with recurrent or metastatic ovarian cancer and endometrial cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Endometrial Cancer
Disease stage
Metastatic disease required
Patients diagnosed with recurrent or metastatic ovarian cancer, endometrial cancer or other solid tumors. Subjects have at least one target lesion as assessed per the RECIST 1.1. Patients with only brain and/or bone lesions as target lesions are ineligible.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: B7-H4-targeted therapy
Have received or is currently receiving ... B7-H4-targeted therapies
Cannot have received: cytotoxic chemotherapy
Have received any of cytotoxic chemotherapy drugs ... within 14 days prior to the first dose of study drug; or need to continue these drugs during the study
Cannot have received: investigational drug
Have received any of ... investigational drugs ... within 14 days prior to the first dose of study drug; or need to continue these drugs during the study
Cannot have received: anti-tumor traditional Chinese medicine
Have received any of ... anti-tumor traditional Chinese medicines ... within 14 days prior to the first dose of study drug; or need to continue these drugs during the study
Cannot have received: endocrine therapy
Have received any of ... endocrine therapy ... within 14 days prior to the first dose of study drug; or need to continue these drugs during the study
Cannot have received: molecular targeted therapy
Have received any of ... molecular targeted therapy ... within 14 days prior to the first dose of study drug; or need to continue these drugs during the study
Cannot have received: biotherapy
Have received any of ... biotherapy ... within 14 days prior to the first dose of study drug; or need to continue these drugs during the study
Cannot have received: macromolecular antitumor drug
Have received macromolecular antitumor drugs (including immunotherapy, such as monoclonal antibodies and bispecific antibodies) within 28 days prior to the first dose of study drug
Cannot have received: radiation therapy
Have received locoregional radiation therapy within 2 weeks prior to the first dose of study drug; more than 30% of bone marrow irradiation or wide-field radiation therapy within 4 weeks prior to the first dose of study treatment
Cannot have received: major surgery
Major surgery (such as craniotomy, thoracotomy or laparotomy, etc.) within 4 weeks prior to the first dose of study treatment
Lab requirements
Blood counts
Inadequate bone marrow reserve or hepatic/renal functions [excluded]
Kidney function
Inadequate bone marrow reserve or hepatic/renal functions [excluded]
Liver function
Inadequate bone marrow reserve or hepatic/renal functions [excluded]
Cardiac function
Cardiological examination abnormality [excluded]; Severe, uncontrolled or active cardiovascular disorders [excluded]
Inadequate bone marrow reserve or hepatic/renal functions. Cardiological examination abnormality. Severe, uncontrolled or active cardiovascular disorders.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify